Long-term Enlarged Survival After an Enhanced Recovery Protocol (LESAS).
NCT ID: NCT04305314
Last Updated: 2022-01-14
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
750 participants
Study Classification
OBSERVATIONAL
Study Start Date
2020-09-01
Study Completion Date
2025-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main objective of this study is to analyze the impact on three years survival of an enhanced recovery program (PRI) after radical surgery for colorectal cancer. As secondary objectives, we propose to analyze the weight of each of the predefined items in the oncological results as well as the quality of life.
We design a multicentric prospective cohort study in people older than 18 years who are going to be operated on for colorectal cancer. 12 hospitals are being selected due to have a PRI implanted according to the RICA pathway published by the Spanish National Health Service. As stated by the literature, the intervention group will be formed for those hospitals with a minimum implementation level of 70% of the PRI and the control group will be the centers that do not reach this level of implementation. Compliance will be studied with 21 key performance indicators and results are analyzed with cancer survival indicators: Overall survival, cancer-specific survival and relapse-free survival). We will also study the time to recurrence, perioperative morbi-mortality, hospital stay and quality of life with the EQ-5D validated questionary.
To create comparable treatment and control groups, the Propensity Index method will be used. To study each variable, multivariate regression will be used. Kaplan-Meier will be used for survival and the log-rank test for comparisons. Significance will be considered if p \<0.05 (two tails).
We design a multicentric prospective cohort study in people older than 18 years who are going to be operated on for colorectal cancer. 12 hospitals are being selected due to have a PRI implanted according to the RICA pathway published by the Spanish National Health Service. As stated by the literature, the intervention group will be formed for those hospitals with a minimum implementation level of 70% of the PRI and the control group will be the centers that do not reach this level of implementation. Compliance will be studied with 21 key performance indicators and results are analyzed with cancer survival indicators: Overall survival, cancer-specific survival and relapse-free survival). We will also study the time to recurrence, perioperative morbi-mortality, hospital stay and quality of life with the EQ-5D validated questionary.
To create comparable treatment and control groups, the Propensity Index method will be used. To study each variable, multivariate regression will be used. Kaplan-Meier will be used for survival and the log-rank test for comparisons. Significance will be considered if p \<0.05 (two tails).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol
NCT06369194
Colorectal Surgery
Critical Pathways
Enhanced Recovery After Surgery
+2 more
ACTIVE_NOT_RECRUITING
Effect of Implementation of Enhanced Recovery After Surgery on 3-year Survival After Colorectal Surgery for Cancer
NCT05002855
Colorectal Cancer
COMPLETED
Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol
NCT03012802
Perioperative Care
Postoperative Complications
Colorectal Surgery
+1 more
COMPLETED
Effects of Incomplete ERAS on Clinical Outcomes in Patients With Colorectal Cancer
NCT05412355
Colorectal Neoplasms
Enhanced Recovery After Surgery
UNKNOWN
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
NCT04595604
Colorectal Cancer
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Subjects of study (inclusion criteria): All patients over 18 years of age who will be operated on a scheduled basis for colorectal cancer within an intensified recovery program (PRI) and who do not present any exclusion criteria.
Exclusion Criteria: - Urgent surgery; -Existence of other concomitant surgical processes; -Patients diagnosed in stage IV cancer; -Patients who refuse to participate.
Participating hospitals: Selected for their interest in intensified recovery and for having established a multidisciplinary team with the program (PRI) for colorectal surgery recommended by the Spanish Ministry of Health. Each center will select from the multidisciplinary team the researchers who will be part of this project as collaborators, ideally the facilitators of the PRI program in that center.
Variables: Patients will be recruited by local researchers from the Anesthesiology and Resuscitation and/or General Surgery services of each participating center before performing the surgical intervention. Informed consent will be requested from all subjects who voluntarily participate in the study.
1. Compliance: As we have commented before and according to the literature, we will define a hospital with an intensified recovery program (PRI) that has a consensus protocol, based on evidence, multidisciplinary, with the support of the center (management) and that has fulfilled more than 70% of the protocol (annex 1) according to the process indicators. The rest of the hospitals will be considered a non-PRI hospital.
2. Demography: Age, sex, BMI, smoking and fitness level of the American Society of Anesthesiologists (ASA). BMI in the surgical indication. Blood transfusion.
3. Comorbidities: Presence of hypertension, diabetes mellitus, coronary artery disease, heart failure, cirrhosis, stroke or transient ischemic attack, COPD / Asthma, atrial fibrillation, heart failure, OSAS. Anemia
4. Related to Surgery and Treatment: Date IQ. Surgical procedure, approach, duration of surgery, estimated bleeding. Curative surgery (R0) or non-R0 (R1-R2). Adjuvant chemotherapy Adjuvant radiotherapy Perioperative transfusion.
5. Variables related to staging: Tumor typology. Growth pattern. Degree of differentiation. Presence of Vascular / lymphatic / perineural invasion / Satellites. Margin affectation. Seal ring cells. K-ras. T tumor piece. No tumor piece. Tumor m. Tumor stage according to AJCC classification.
6. Related to the follow-up:
In-hospital complications at 60 days of follow-up that will be recorded are: surgical complications, infectious complications, cardiovascular complications and other types of complications. Each complication will be classified as mild, moderate or severe. The Clavien-Dindo classification will also be used. Perioperative mortality: The number and percentage of deaths within 60 days of surgery. Hospital Stay: hospital stay is defined as the duration in days from the date of admission to hospital discharge. Quality of life according to the EuroQol Five questionnaire. (EQ-5D).
Overall mortality: The number and percentage of deaths occurred since the intervention until the end of the follow-up period. Overall survival: patients alive from surgery to the last control. Disease-free survival: number of patients alive and without cancer recurrence from the intervention period until the end of follow-up.
Disease recurrence: detected by CT or FCC, from the day of the intervention until the end of the follow-up.
Patient Follow-up Plan: 5 years after surgery. Data collection: The data will be collected in individual hospitals on a paper CRD for each patient recruited. This will include patient identification data in order to allow monitoring of clinical results. The data will be encoded by generating a unique numerical code and transcribed by local researchers in a database using an electronic CRD (eCRD). The data collection platform used will be Castor EDC https://www.castoredc.com/. Castor EDC complies with all applicable laws and regulations: good clinical practice (GCP), 21 CFR Part 11, EU Annex 11 and the European Data Protection Directive. Each patient will only be identified in the electronic CRD by their numerical code. In each center a list of patients will be used to match the identification codes of the individual patients' database in order to record the clinical results and provide any of the missing data. All identifiable data collected, processed and stored for the purposes of the project will be kept confidential at all times and will comply with the guidelines of Good Clinical Practice for Research (GCP) and the General Data Protection Regulation (GDPR) (Regulation (EU) ) 2016/679).
Data analysis: Sample size: understanding, according to the literature, that only 60% of the centers with a PRI achieve more than 70% of compliance, we consider the scenario of 6 PRI and 4 non-PRI centers adequate among the 10 who collaborate in this research project. Estimating a difference in overall survival between centers around 10% (65% vs. 75%), with a power of 80%, a 95% confidence and 5% of possible losses, a minimum sample size of 366 is estimated patients in each group (732 patients in total). For the study of survival, only patients with a minimum follow-up of two years (first 12 months of the study) will be considered. However, they will continue to be recruited until the end of the three years for the study of secondary objectives.
Understanding that the main objective, study of survival, may be subject to inherent aspects of each center, independent of the intervention, it is necessary to create comparable treatment and control groups for which the Propensity Score (Propensity Score Matching) method will be used. A descriptive analysis of the data will be carried out: Qualitative variables will be presented by frequency distribution of the percentages of each category. The quantitative variables studied will be explored with the Kolmogorov - Smirnov conformity test. Bivariate Analysis Comparison between variables (factors): The association between the factors will be investigated by hypothesis contrast tests, with comparison of proportions when both variables are qualitative (chi square, Fisher's exact test), mean comparisons when one of them is quantitative (Student's t, ANOVA, and if they do not follow the normal distribution, the Mann-Whitney U test or the Kruskall-Wallis test) and bivariate correlations (Coef. Pearson Correlation) when both are quantitative or, if the conditions are not met of application, the Spearman correlation. For comparisons in related samples when one of them is quantitative, Student's t-test and/or ANOVA will be used for repeated measurements and Wilcoxon or Friedman's test when do not follow normal distribution). Multivariate analysis: To study the relationship of each variable controlling the possible effect caused by third variables. The analysis will be completed using multivariate regression models. Survival analyzes will be performed using the Kaplan-Meier method for survival comparisons the log-rank test will be used. The effects will be considered significant if p \<0.05.
Monitoring and audit: The data collection documents will be audited to ensure that study activities are carried out in accordance with the protocol, good clinical practice and applicable regulatory requirements. In the participating hospitals, local study documents can be selected for local auditing. The quality of the data will be audited.
Limitations of the study: Those of a prospective non-randomized study. Difficulty in recruiting patients for potential structural or multidisciplinary team problems. Inappropriate number of patients in any of the arms due to a very high or very low level of compliance.
Exclusion Criteria: - Urgent surgery; -Existence of other concomitant surgical processes; -Patients diagnosed in stage IV cancer; -Patients who refuse to participate.
Participating hospitals: Selected for their interest in intensified recovery and for having established a multidisciplinary team with the program (PRI) for colorectal surgery recommended by the Spanish Ministry of Health. Each center will select from the multidisciplinary team the researchers who will be part of this project as collaborators, ideally the facilitators of the PRI program in that center.
Variables: Patients will be recruited by local researchers from the Anesthesiology and Resuscitation and/or General Surgery services of each participating center before performing the surgical intervention. Informed consent will be requested from all subjects who voluntarily participate in the study.
1. Compliance: As we have commented before and according to the literature, we will define a hospital with an intensified recovery program (PRI) that has a consensus protocol, based on evidence, multidisciplinary, with the support of the center (management) and that has fulfilled more than 70% of the protocol (annex 1) according to the process indicators. The rest of the hospitals will be considered a non-PRI hospital.
2. Demography: Age, sex, BMI, smoking and fitness level of the American Society of Anesthesiologists (ASA). BMI in the surgical indication. Blood transfusion.
3. Comorbidities: Presence of hypertension, diabetes mellitus, coronary artery disease, heart failure, cirrhosis, stroke or transient ischemic attack, COPD / Asthma, atrial fibrillation, heart failure, OSAS. Anemia
4. Related to Surgery and Treatment: Date IQ. Surgical procedure, approach, duration of surgery, estimated bleeding. Curative surgery (R0) or non-R0 (R1-R2). Adjuvant chemotherapy Adjuvant radiotherapy Perioperative transfusion.
5. Variables related to staging: Tumor typology. Growth pattern. Degree of differentiation. Presence of Vascular / lymphatic / perineural invasion / Satellites. Margin affectation. Seal ring cells. K-ras. T tumor piece. No tumor piece. Tumor m. Tumor stage according to AJCC classification.
6. Related to the follow-up:
In-hospital complications at 60 days of follow-up that will be recorded are: surgical complications, infectious complications, cardiovascular complications and other types of complications. Each complication will be classified as mild, moderate or severe. The Clavien-Dindo classification will also be used. Perioperative mortality: The number and percentage of deaths within 60 days of surgery. Hospital Stay: hospital stay is defined as the duration in days from the date of admission to hospital discharge. Quality of life according to the EuroQol Five questionnaire. (EQ-5D).
Overall mortality: The number and percentage of deaths occurred since the intervention until the end of the follow-up period. Overall survival: patients alive from surgery to the last control. Disease-free survival: number of patients alive and without cancer recurrence from the intervention period until the end of follow-up.
Disease recurrence: detected by CT or FCC, from the day of the intervention until the end of the follow-up.
Patient Follow-up Plan: 5 years after surgery. Data collection: The data will be collected in individual hospitals on a paper CRD for each patient recruited. This will include patient identification data in order to allow monitoring of clinical results. The data will be encoded by generating a unique numerical code and transcribed by local researchers in a database using an electronic CRD (eCRD). The data collection platform used will be Castor EDC https://www.castoredc.com/. Castor EDC complies with all applicable laws and regulations: good clinical practice (GCP), 21 CFR Part 11, EU Annex 11 and the European Data Protection Directive. Each patient will only be identified in the electronic CRD by their numerical code. In each center a list of patients will be used to match the identification codes of the individual patients' database in order to record the clinical results and provide any of the missing data. All identifiable data collected, processed and stored for the purposes of the project will be kept confidential at all times and will comply with the guidelines of Good Clinical Practice for Research (GCP) and the General Data Protection Regulation (GDPR) (Regulation (EU) ) 2016/679).
Data analysis: Sample size: understanding, according to the literature, that only 60% of the centers with a PRI achieve more than 70% of compliance, we consider the scenario of 6 PRI and 4 non-PRI centers adequate among the 10 who collaborate in this research project. Estimating a difference in overall survival between centers around 10% (65% vs. 75%), with a power of 80%, a 95% confidence and 5% of possible losses, a minimum sample size of 366 is estimated patients in each group (732 patients in total). For the study of survival, only patients with a minimum follow-up of two years (first 12 months of the study) will be considered. However, they will continue to be recruited until the end of the three years for the study of secondary objectives.
Understanding that the main objective, study of survival, may be subject to inherent aspects of each center, independent of the intervention, it is necessary to create comparable treatment and control groups for which the Propensity Score (Propensity Score Matching) method will be used. A descriptive analysis of the data will be carried out: Qualitative variables will be presented by frequency distribution of the percentages of each category. The quantitative variables studied will be explored with the Kolmogorov - Smirnov conformity test. Bivariate Analysis Comparison between variables (factors): The association between the factors will be investigated by hypothesis contrast tests, with comparison of proportions when both variables are qualitative (chi square, Fisher's exact test), mean comparisons when one of them is quantitative (Student's t, ANOVA, and if they do not follow the normal distribution, the Mann-Whitney U test or the Kruskall-Wallis test) and bivariate correlations (Coef. Pearson Correlation) when both are quantitative or, if the conditions are not met of application, the Spearman correlation. For comparisons in related samples when one of them is quantitative, Student's t-test and/or ANOVA will be used for repeated measurements and Wilcoxon or Friedman's test when do not follow normal distribution). Multivariate analysis: To study the relationship of each variable controlling the possible effect caused by third variables. The analysis will be completed using multivariate regression models. Survival analyzes will be performed using the Kaplan-Meier method for survival comparisons the log-rank test will be used. The effects will be considered significant if p \<0.05.
Monitoring and audit: The data collection documents will be audited to ensure that study activities are carried out in accordance with the protocol, good clinical practice and applicable regulatory requirements. In the participating hospitals, local study documents can be selected for local auditing. The quality of the data will be audited.
Limitations of the study: Those of a prospective non-randomized study. Difficulty in recruiting patients for potential structural or multidisciplinary team problems. Inappropriate number of patients in any of the arms due to a very high or very low level of compliance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Major Surgery
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1: PRI > 70%
Compliance with the Enhanced Revovery protocol higher than 70%
PRI (Enhanced Recovery after surgery protocol)
Intervention Type
OTHER
Standard use of Spanish perioperative guidelines (PRI)
Group 2: PRI < 70%
Compliance with the Enhanced Revovery protocol lower than 70%
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PRI (Enhanced Recovery after surgery protocol)
Standard use of Spanish perioperative guidelines (PRI)
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients over 18 years of age who will be operated on a scheduled basis for colorectal cancer
Exclusion Criteria
* \- Urgent surgery; -Existence of other concomitant surgical processes; -Patients diagnosed in stage IV cancer; -Patients who refuse to participate.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Instituto de Salud Carlos III
OTHER_GOV
Sponsor Role
collaborator
Instituto de Investigación Sanitaria Aragón
OTHER
Sponsor Role
collaborator
Grupo Español de Rehabilitación Multimodal
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jose M Ramirez, Prof.
Role: PRINCIPAL_INVESTIGATOR
Universidad de Zaragoza
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital General Universitario de Elche
Elche, Alicante, Spain
Site Status
RECRUITING
Complejo Hospitalario de Navarra
Pamplona, Navarre, Spain
Site Status
RECRUITING
Hospital de la Ribera
Alzira, , Spain
Site Status
RECRUITING
Hospital de Barbastro
Barbastro, , Spain
Site Status
RECRUITING
Hospital Universitario de Guadalajara
Guadalajara, , Spain
Site Status
RECRUITING
Hospital General Universitario Gregorio Marañón
Madrid, , Spain
Site Status
RECRUITING
Hospital Jiménez Diaz
Madrid, , Spain
Site Status
RECRUITING
Hospital Universitario Infanta Leonor
Madrid, , Spain
Site Status
RECRUITING
Complejo Asistencial Universitario de Palencia
Palencia, , Spain
Site Status
RECRUITING
Hospital General de Valencia
Valencia, , Spain
Site Status
RECRUITING
Hospital Clínico Universitario Lozano Blesa
Zaragoza, , Spain
Site Status
RECRUITING
Hospital Universitario Miguel Servet
Zaragoza, , Spain
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Spain
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Ramirez-Rodriguez JM, Martinez-Ubieto J, Munoz-Rodes JL, Rodriguez-Fraile JR, Garcia-Erce JA, Blanco-Gonzalez J, Del Valle-Hernandez E, Abad-Gurumeta A, Centeno-Robles E, Martinez-Perez C, Leon-Arellano M, Echazarreta-Gallego E, Elia-Guedea M, Pascual-Bellosta A, Miranda-Tauler E, Manuel-Vazquez A, Balen-Rivera E, Alvarez-Martinez D, Perez-Pena J, Abad-Motos A, Redondo-Villahoz E, Biosta-Perez E, Guadalajara-Labajo H, Ripolles-Melchor J, Latre-Saso C, Cordoba-Diaz de Laspra E, Sanchez-Guillen L, Cabellos-Olivares M, Longas-Valien J, Ortega-Lucea S, Ocon-Breton J, Arroyo-Sebastian A, Garcia-Olmo D. Surgical treatment for colorectal cancer: analysis of the influence of an enhanced recovery programme on long-term oncological outcomes-a study protocol for a prospective, multicentre, observational cohort study. BMJ Open. 2020 Oct 27;10(10):e040316. doi: 10.1136/bmjopen-2020-040316.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GERMFIS2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Feasibility and Impact of a Prehabilitation and Rehabilitation Program for the Continuity of Care in Severe Low Anterior Resection Syndrome.
NCT04612569
UNKNOWN
Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol in Gastric Surgery for Cancer
NCT03865810
UNKNOWN
Enhanced Recovery After Surgery Program for Colorectal Cancer: a Multi-center Study (ERASC1)
NCT03126058
UNKNOWN
NA
ERAS Program Items Adherence, PROMs and RIOT After Colorectal Surgery
NCT04397627
UNKNOWN
Compliance With ERAS and Five Year Survival After Colorectal Cancer Treatment
NCT06342687
COMPLETED
Effects of Implementing an ERAS Protocol
NCT06010225
COMPLETED
Enhanced Recovery and Patient Blood Management in Colorectal Surgery
NCT05227014
UNKNOWN
Enhanced Recovery Program After Laparoscopic Colon Cancer Surgery
NCT02399631
TERMINATED
NA
Impact Of The Nurse Enhanced Recovery After Surgery Coordinator On The Compliance In Colorectal Surgery (nursERAS-BCN)
NCT05231473
COMPLETED
NA
POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + 3)
NCT06790238
ACTIVE_NOT_RECRUITING
Early Discharge After Robotic Colorectal Surgery (eRCS): a Prospective Observational Study
NCT05408182
UNKNOWN
PREHABILITATION RECTAL CANCER DURING ADJUVANCY VS BEFORE SURGERY
NCT03543514
UNKNOWN
ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Colorectal Cancer Surgery
NCT04037787
COMPLETED
NA
ERAS in Laparoscopic Surgery for Colorectal Cancer: Risk Factors for Delayed Recovery
NCT02527967
COMPLETED
Postopoperarive Outcomes After Colorectal Surgery in Europe (euroPOWER)
NCT03814681
UNKNOWN
Clinical and Economical Evaluation of Colorectal Surgery in Ambulatory Care
NCT03760939
TERMINATED
NA
Reconstruction Techniques and Vascular Approach After Laparoscopic Left Hemicolectomy and Rectum Low Anterior Resection
NCT02746224
COMPLETED
NA
Feasibility and Effects of an Enhanced Recovery vs Conventional Care After Emergency Colon Surgery for Patients With Left Colon Perforation.
NCT03611413
COMPLETED
Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance
NCT06936774
NOT_YET_RECRUITING
PHASE3
Prehabilitation in Geriatric Patients With Colorectal Neoplasia
NCT05851235
UNKNOWN
NA
Assessment of Symptoms and Consequences of Coloanal Continuity Reconstruction
NCT03292289
COMPLETED
NA
Bowel Dysfunction After Rectal Cancer Treatment
NCT05020132
COMPLETED
Quality of Life After Enhanced Recovery Protocol for Colorectal Surgery
NCT02824783
COMPLETED
Selection of Surgical Technique in Rectal Cancer
NCT06442215
RECRUITING
Economic and Clinical Evaluation of Enhanced Recovery in Colorectal Surgery
NCT01610726
COMPLETED
NA